Replimune Group: Analysts Are More Optimistic Than The Market
2025-05-16 14:22:30 ET
Summary
- REPL shares fell sharply recently on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma.
- RP1, combined with Opdivo, shows strong Phase 2 data and could address a significant unmet need in anti-PD-1 failed advanced melanoma.
- Skepticism persists around the oncolytic virus approach, but Iovance's slow Amtagvi launch leaves market opportunity for Replimune.
- An analysis around Replimune Group follows in the paragraphs below.
Shares of oncolytic immunotherapy concern Replimune Group, Inc. ( REPL ) plunged 28% in two trading sessions (May 6-7, 2025) on big volume with no company or advanced melanoma news. Its lead therapy (RP1) in combination with anti-PD-1 therapy, Opdivo, has a July 22, 2025, PDUFA date as a second-line (2L) therapy for the treatment of anti-PD-1 failed advanced melanoma. With solid data backing its application but lingering reservations concerning the oncolytic virus therapy approach, the recent unexplained drop in this clinical stage biotech concern merited further investigation. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Replimune Group: Analysts Are More Optimistic Than The Market
NASDAQ: REPL
REPL Trading
10.12% G/L:
$5.1199 Last:
764,176 Volume:
$4.90 Open:
